Debt And Cash FlowThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Market OutlookThe price target has been reduced from $3.00 to $1.00, indicating a more cautious outlook on the stock.
Regulatory ChallengesAn additional confirmatory Phase 3 trial for apraglutide in short bowel syndrome is needed for approval, adding financial uncertainty to the company.